OpenAI expands partnership with Moderna for customizable GPTs
Mobi Health News
APRIL 26, 2024
The pharma giant's employees will have access to ChatGPT Enterprise, which allows teams to create customized GPTs on specific topics.
topics pharma 
What AI Changes Will We See In Big Pharma This Year?
Electronic Health Reporter
APRIL 8, 2022
Shannon Flynn is a freelance blogger who covers education technologies, cybersecurity and IoT topics. The article What AI Changes Will We See In Big Pharma This Year? You can follow Shannon on Muck Rack or Medium to read more of her articles. Artificial intelligence (AI) has had major impacts in the health care […].
162 Join 50,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
OCTOBER 11, 2023
The selections feature topics ranging from a review of the regulatory consequences of the FDA’s accelerated approval of eteplirsen, to a comparison of the safety and effectiveness of generic and brand-name fluticasone-salmeterol for COPD, to an analysis of free speech challenges to Medicare drug price negotiation under the Inflation Reduction Act.
Patient Advocacy 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JULY 28, 2023
The selections feature topics ranging from a review of modifications to blood glucose monitoring systems and related patent protections, an examination of insulin price changes from 2012-2019, and a discussion of why a proposed federal bill that would ban government health care programs from using the quality-adjusted life-year is misguided.
Medicaid 130
130 
Doceree is Bringing Pharma Advertising to EHR and Telehealth
Healthcare IT Today
AUGUST 7, 2020
In the nearly 15 years that we’ve been writing about EHR and health IT here at Healthcare IT Today, one of the most interesting topics we cover is pharma advertising inside an EHR or other health IT software product. It’s a topic that will likely never disappear since Pharma has a lot of money to […].
Telemedicine 103
103 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
OCTOBER 28, 2022
The selections feature topics ranging from an examination of Park doctrine prosecutions of executives of pharmaceutical and medical device companies, an analysis of patent thickets covering biologic drugs, and a discussion of product hopping strategies among manufacturers of inhalers. N Engl J Med. 2022 Sep 29;387(13):1153-1156.
FDA 241
241 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JANUARY 18, 2023
The selections feature topics ranging from a discussion of antitrust as a tool to address patent thickets, to an analysis of the relationship between price and efficacy for recently approved cancer drugs, to an examination of the viability and implications of preemption challenges to state laws restricting medication abortion. J Law Biosci.
Public Health 205
205 Public Health 205
205 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MAY 22, 2023
The selections feature topics ranging from an analysis of government and industry investments for recently approved drugs, to a discussion of court decisions on mifepristone, and an examination of the added therapeutic benefit associated with the top-selling brand-name drugs in Medicare. Arthritis Rheumatol. 2023 Apr 7. Epub ahead of print].
How Wolters Kluwer Health Keeps Large Language Models and AI Honest
Healthcare IT Today
DECEMBER 7, 2023
And there are intriguing—if currently less trustworthy—additions from self-monitoring devices, pharma clinics, and predictive analytics. UpToDate stores information on 12,000 topics in 25 medical specialties, based on medical literature and curated by leading experts in each field. No one can keep up with the discoveries in each field.
Doctors 113
113 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JUNE 20, 2023
The selections feature topics ranging from an investigation of federal support for the development of expensive HIV drugs, to an analysis of COPD exacerbations and hospitalizations among new users of maintenance inhalers, to a comparison of sales for new drugs with and without an initial orphan drug designation. 2023 May 9;329(18):1607-1608.
FDA 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
DECEMBER 27, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues.
Medicare 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MARCH 24, 2023
The selections feature topics ranging from an analysis of the approval and marketing of biosimilars with a skinny label and their associated Medicare savings, to a discussion of the Philips Respironics recall and the need for reforms to U.S. Below are the citations for papers identified from the month of February. Lancet Diabetes Endocrinol.
Medicare 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JULY 1, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues.
FDA 205
205 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
APRIL 21, 2023
The selections feature topics ranging from an analysis of patent challenges by generic manufacturers on brand-name inhalers, a discussion of the Alliance for Hippocratic Medicine v. The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. N Engl J Med. 2023 Mar 9;388(10):e29.
COVID-19 Vaccine 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JANUARY 19, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues.
COVID-19 176
176 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
NOVEMBER 17, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Below are the abstracts/summaries for papers identified from the month of October. Walsh BS, Kesselheim AS, Rome BN. Medicaid Spending on Antiretrovirals from 2007-2019. Clin Infect Dis. 2022 Oct 21:ciac833. Epub ahead of print.
FDA 184
184 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MAY 19, 2022
The selections feature topics ranging from a discussion of manufacturer’s restricted delivery of 340B drugs to contract pharmacies and ensuing litigation, to an analysis mapping the European patent landscape for medical uses of known products, to an evaluation of the clinical benefit of novel drugs approved in the U.S. from 2018-2019.
Health Insurance 205
205 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
JULY 15, 2022
The selections feature topics ranging from a discussion of potential pathways to enable government patent use before nonpatent exclusivities expire, to an examination of medical oncologists who receive more than $100,000 annually from pharmaceutical companies, to an analysis of the launch prices of new drugs from 2008-2021. 2022 Jun 5.
Public Health 205
205 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
AUGUST 26, 2022
The selections feature topics ranging from how Wikipedia pages communicate drug efficacy information, to addressing pharmaceutical industry payments to physicians, to the frequency with which the Food and Drug Administration removes hazardous dietary supplements from the market. J Health Polit Policy Law. 2022 Jul 14:10041247.
Weekly Roundup – January 13, 2024
Healthcare IT Today
JANUARY 13, 2024
Not surprisingly, we got a lot of good responses from the Healthcare IT Today community on this topic. Read more… 2024 Health IT Predictions : AI in Pharma. Read more… What Topic Aren’t People Talking About Enough? Read more… 2024 Health IT Predictions: Generative AI and Data. CHIME 2023 Edition.
Compliance 104
104 
‘Care Anywhere’ is the new normal, according to new industry report
Healthcare It News
FEBRUARY 1, 2022
Before joining BCGDV, they practised as medical doctors or worked in industries such as health insurance, medtech or pharma”, the company spokesperson informed Healthcare IT News. The growing demand for virtual mental health care was also a panel discussion topic at HIMSS21 APAC Conference last November. ON THE RECORD.
COVID-19 216
216 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
OCTOBER 7, 2022
The selections feature topics ranging from a discussion of opportunities for improving the use of U.S. The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Below are the citations for papers identified from the month of August. 2022 Aug 9;328(6):580-582.
‘Care Anywhere’ is the new normal, according to industry report
Healthcare It News
FEBRUARY 1, 2022
Before joining BCGDV, they practised as medical doctors or worked in industries such as health insurance, medtech or pharma”, the company spokesperson informed Healthcare IT News. The growing demand for virtual mental health care was also a panel discussion topic at HIMSS21 APAC Conference last November. ON THE RECORD.
COVID-19 207
207 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
APRIL 25, 2022
The selections feature topics ranging from a discussion of patient assistance programs and the Anti-Kickback Statute, to an analysis of the effects of state opioid prescribing laws on the use of opioids and other pain treatments, to an evaluation of the association between regulatory drug safety advisories and changes in drug use.
COVID-19 144
144 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MARCH 25, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues.
FDA 205
205 
Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
FEBRUARY 23, 2022
The post Monthly Round-Up of What to Read on Pharma Law and Policy appeared first on Bill of Health. Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues.
Medicaid 144
144 
Nurse-1-1 Raises $2.3M to Expand Conversational Marketing for Healthcare
HIT Consultant
MARCH 31, 2022
. – The company will use the financing to expand its team, accelerate its go-to-market efforts, and scale its current partnerships with publicly traded and nationwide digital health, at-home testing, and pharma companies. Nationwide Nurse Work. Simplify prescription adherence, at-home testing, and more.
Nurses 52
52 
Announcements, Insights, and Perspectives from the Oracle Health Conference
Healthcare IT Today
SEPTEMBER 20, 2023
OracleHealth #oraclehc — John Lynn (@techguy) September 19, 2023 Another not surprising topic was Oracle Health’s efforts to bridge the clinical systems (EHR) and the business systems (ERP). Not surprising that pharma wants more real world data. The US EHR market is quite saturated, but the same isn’t true internationally.
Hospitals 110
110 Hospitals 110
110 
Drug Price Transparency: Planning for Change
HIT Consultant
NOVEMBER 8, 2022
And given the fact that prescription drug prices continue to increase, the topic of drug price management is likely to continue to capture the attention of the media and policymakers at the state level, given the current lack of overriding federal regulation. As a result, pharma manufacturers are looking to software vendors to fill the void.
Weekly Roundup – January 28, 2023
Healthcare IT Today
JANUARY 28, 2023
John spoke with Lucia Savage at Omada Health and AcademyHealth about information blocking, medical misinformation, SDoH, and other key topics at next month’s Health Datapalooza. IT staffing company Talent Group acquired Queen Consulting Group , which specializes in Epic implementations and other areas of health and pharma IT.
HIPAA 108
108 HIPAA 108
108 
While Virtual Care is “Table Stakes” in Health Care, Consumers Are Growing More Protective About Data-Sharing
Jane Sarashon
MARCH 18, 2024
Other precipitous falls in willingness-to-share-health-data occurred between consumers vis-a-vis research organizations (a stunning drop of roughly 50% (from 35% of consumers in 2020 to 18% in 2023), insurance companies (53% to 45%), health tech companies (falling from 25% to 14%), and pharma companies (dropping 22% to 13%).
COVID-19 70
70 
Why Health Tech Firms Must Hire Chief Medical Officers
HIT Consultant
JUNE 18, 2023
At a glance, the CMO serves as a scientific leader for partnerships with pharma companies which stimulate health tech companies’ strategies and operations. The CMO will need to meet the requirements and demands of your organization.
COVID-19 98
98 
Weekly Roundup – June 3, 2023
Healthcare IT Today
JUNE 3, 2023
It’s important to address a meaningful need, find collaborators in the pharma or provider markets, and validate proof points for customers and regulators , the expert said. In the latest Healthcare IT Podcast, John and Colin tackle the topic on everyone’s mind. Read more… Is AI Eating Healthcare ?
Fraud 103
103 Fraud 103
103 
Weekly Roundup – October 1, 2022
Healthcare IT Today
OCTOBER 1, 2022
There’s a lot of nuance to whether healthcare tech is a cause or solution to burnout , John learned in a conversation with three experts on the topic. Lyfegen announced an $8 million oversubscribed $8 million Series A financing round ; the startup makes value-based contracting software for pharma.
Doctors 107
107 
Americans’ Trust in U.S. Healthcare Lags Tech — and Women Are Particularly Cynical
Health Populi
APRIL 24, 2019
In this study, the healthcare industry is comprised of five segments: hospitals and clinics; pharma; biotech (separate from pharma); consumer health (e.g., ” Cost continues to be top-of-mind for healthcare consumers, who largely blame pharma first in the Edelman research. over-the-counter medicines); and, health insurance.
The Most Relevant Companies in Health Care – Learning From the W2O Group
Health Populi
MARCH 3, 2021
For example, in 2019, some of the big health care issues for consumers were politics (in general), women’s health, the opioid crisis, and vaping/tobacco — for which dots didn’t connect nearly as intimately as the 2020 top 5 topics. These ten are all life science/pharma companies. The top ten were: AstraZeneca.
COVID-19 68
68 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems.
Governance 60
60 Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems.
Governance 60
60 Governance 60
60 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems. Comments Comments.
Governance 60
60 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems. Comments Comments.
Governance 60
60 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems. Comments Comments.
Governance 60
60 Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems.
Governance 60
60 Governance 60
60 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems.
Governance 60
60 Governance 60
60 
Ruchin Kansal and Strategic Partnerships: To Go Far, Go Together – Harlow On Healthcare
Health Blawg
OCTOBER 15, 2018
This edition’s topic is strategic partnerships, and I had the chance to speak about them with Ruchin Kansal ( @kansalruchin ), the Digital Business Strategy leader for Healthcare, Insurance and Life Sciences at Virtusa. He sees an opportunity for everyone involved to benefit in terms of solving clinical problems.
Governance 60
60 Governance 60
60 
Let's personalize your content